This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, et al. Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Eur Heart J. 2018;39:2314–25.
Yonezawa Y, Horinaka S, Shirakawa C, Kogure Y. Estimated glomerular filtration ratio is a better index than creatinine clearance (Cockcroft-Gault) for predicting the prevalence of atrial fibrillation in the general Japanese population. Hypertens Res. 2018;41:451–9.
Providencia R, Marijon E, Boveda S, Barra S, Narayanan K, Le Heuzey JY, et al. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation. Am J Cardiol. 2014;114:646–53.
Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625–35.
Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129:961–70.
Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017;11:Cd011373.
Yao X, Tangri N, Gersh BJ, Sangaralingham LR, Shah ND, Nath KA, et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017;70:2621–32.
Eto M, Barandier C, Rathgeb L, Kozai T, Joch H, Yang Z, et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res. 2001;89:583–90.
Sanada F, Taniyama Y, Muratsu J, Otsu R, Iwabayashi M, Carracedo M, et al. Activated factor X induces endothelial cell senescence through IGFBP-5. Sci Rep. 2016;6:35580.
Ichikawa H, Shimada M, Narita M, Narita I, Kimura Y, Tanaka M, et al. Rivaroxaban, a direct factor Xa inhibitor, ameliorates hypertensive renal damage through inhibition of the inflammatory response mediated by protease-activated receptor pathway. J Am Heart Assoc. 2019;8:e012195.
Suzuki M, Fukamizu S, Oyama J, Mizukami A, Matsumura A, Hashimoto Y, et al. Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: the X-NOAC study. Int J Cardiol. 2015;188:52–3.
Acknowledgements
The authors would like to thank the patients and investigators for their participation in the study and Ms. Hiroko Takagi (Saga University, Saga, Japan) for her excellent support as a study secretariat. We also thank Mr. Hirokazu Yamada and Mr. Yasushi Kanamori (Soiken Holdings Inc., Osaka, Japan) for their statistical support.
Funding
The study was funded by Bayer Yakuhin, Ltd.
Author information
Authors and Affiliations
Contributions
All authors were X-NOAC Study Investigators and contributed to the planning and conduction of the study and data acquisition. KN was a principal investigator in the study. AT analyzed and interpreted the data, prepared the figures and tables, and wrote the paper. All authors critically reviewed the paper and approved the final version of the paper.
Corresponding authors
Ethics declarations
Conflict of interest
MS received remuneration for lecture from Otsuka, Bayer, Daiichi Sankyo, Biotronik, Medtronic, and Fukuda Denshi. JO belonged to the endowed department of Fukuda Denshi. KN received honoraria from Eli Lilly, Astellas, Ono, Takeda, Daiichi Sankyo, Boehringer Ingelheim, MSD, Mitsubishi Tanabe, AstraZeneca; research grants from Amgen, Teijin, Terumo, Mitsubishi Tanabe, Asahi Kasei, Astellas, Boehringer Ingelheim, and Bayer and scholarships from Bayer, Daiichi Sankyo, Teijin, Astellas, Takeda, and Bristol-Myers Squibb. The other authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Tanaka, A., Suzuki, M., Matsunaga, K. et al. Effect of rivaroxaban on urinary albumin excretion in patients with atrial fibrillation and chronic kidney disease: a randomized trial (X-NOAC). Hypertens Res 43, 571–574 (2020). https://doi.org/10.1038/s41440-019-0384-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41440-019-0384-6